Abstract | BACKGROUND: MATERIALS AND METHODS: RESULTS: The study included 37 patients (19 female); median age was 55 years (range 26-87); and histologies included LMS (22), SS (11), and MPNST (4). The DCR was 46% (17/37). Median progression-free survival was 13.4 weeks. The RECIST response rate was 14% (5/37). The Choi response rate was 51% (19/37). Median overall survival was 13.2 months. Of the first 25 patients, 15 (60%) required dacarbazine dose reductions for hematologic toxicity, with one episode of grade 5 neutropenic fever. After reducing the starting dose of dacarbazine to 850 mg/m2, only 3 of the final 12 (25%) patients required dose reduction. CONCLUSION: This phase II study met its primary endpoint with an 18-week DCR of 46%. The clinical activity of dacarbazine plus sorafenib in patients with these diagnoses is modest. IMPLICATIONS FOR PRACTICE:
|
Authors | David R D'Adamo, Mark A Dickson, Mary L Keohan, Richard D Carvajal, Martee L Hensley, Catherine M Hirst, Marietta O Ezeoke, Linda Ahn, Li-Xuan Qin, Cristina R Antonescu, Robert A Lefkowitz, Robert G Maki, Gary K Schwartz, William D Tap |
Journal | The oncologist
(Oncologist)
Vol. 24
Issue 6
Pg. 857-863
(06 2019)
ISSN: 1549-490X [Electronic] England |
PMID | 30126857
(Publication Type: Clinical Trial, Phase II, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Copyright | © AlphaMed Press 2018. |
Chemical References |
|
Topics |
- Administration, Oral
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, adverse effects)
- Dacarbazine
(administration & dosage, adverse effects)
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Feasibility Studies
- Febrile Neutropenia
(diagnosis, epidemiology, etiology)
- Female
- Humans
- Leiomyosarcoma
(drug therapy, mortality, pathology)
- Male
- Middle Aged
- Neurofibrosarcoma
(drug therapy, mortality, pathology)
- Progression-Free Survival
- Response Evaluation Criteria in Solid Tumors
- Sarcoma, Synovial
(drug therapy, mortality, pathology)
- Severity of Illness Index
- Sorafenib
(administration & dosage, adverse effects)
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|